Skip to main content
OpenTrials
Completed

NCT Number: NCT05071352

Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study

The aim of this prospective, randomized, active control, double blinded study is to assess the effect and safety of continuous infusion nefopam in mechanically ventilated ICU patients compared to standard of care. It is being hypothesized that continuous infusion nefopam will reduce opioid use with acceptable safety profile compared to standard of care.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Pain is defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage". Critically ill patients experience pain at rest and during standard caring procedures. Arterial catheter insertion, chest tube removal, wound drain removal, wound care, and turning are associated with the greatest increased pain intensity. Pain have short and long-term sequelae on critically ill patients. Short-term sequelae include impaired tissue oxygenation, impaired wound healing, and impaired immune functions. Long-term sequelae include chronic pain, Post-traumatic stress disorder (PTSD) symptoms, and a lower health-related quality of life.

The gold standard for pain assessment is patient's self-report of pain. For critically ill able to self-report pain the 0-10 numeric rating scale in a visual format (NRS-V) is the best to use. Unfortunately, a lot of critically ill patients are unable to communicate and self-report pain. So, using behavioral pain scales are suitable in this type of patients, Critical care pain observation tool (CPOT) demonstrates validity and reliability for monitoring pain in critical ill adult patient who are unable to self-report pain and in whom behaviors are observable. The 2018 Pain, Agitation/sedation, Delirium, Immobility, and Sleep disruption (PADIS) guideline panel suggests "using an assessment-driven, protocol-based, stepwise approach for pain and sedation management in critically ill adults" and state as a good practice statement "critically ill adults should be regularly assessed for delirium using a valid tool".

Opioids are a cornerstone in the management of pain in critically ill patient, but have a lot of negative consequences including constipation, urinary retention, bronchospasm, over-sedation, respiratory depression, hypotension, nausea, truncal rigidity, delirium, and immunosuppression. Also, they contribute to vasodilatation and hypotension which lead to increased resuscitation fluids volume in critically ill patient.

"Multi-modal analgesia" also known as "balanced analgesia" approach via using non-opioids adjuvant or in replacement of opioids to target different pain pathways leads to optimizing analgesia and reducing opioids consumption. In France, the second most prescribed non-opioids in mechanically ventilated intensive care unit (ICU) patient is nefopam. Nefopam is a non-opioid, non-steroidal centrally acting analgesic, although the exact mechanism of action poorly understood, analgesic activity is thought to be via inhibiting dopamine, norepinephrine, serotonin reuptake. Nefopam was non-inferior to fentanyl for pain control in patients undergoing elective cardiac surgery without increase in adverse effects. Nefopam has a fentanyl sparing effect up to 50% in patients underwent laparoscopic total hysterectomy.

The 2018 PADIS guideline panel made a conditional recommendation for using "nefopam (if feasible) either as an adjunct or replacement for an opioid to reduce opioid use and their safety concerns for pain management in critically ill adults".

Therefore, the aim of this prospective, randomized, active control, double blinded study is to assess the effect and safety of continuous infusion nefopam in mechanically ventilated ICU patients compared to standard of care. It is being hypothesized that continuous infusion nefopam will reduce opioid use with acceptable safety profile compared to standard of care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients >18 years on mechanical ventilation and expected to need ventilatory support for the next 24 hours.
  • Candidate for sedation and analgesia protocol

Exclusion criteria

  • Pregnant and/or lactating woman.
  • Has been intubated for duration longer than 12 hours in an intensive care unit.
  • Proven or suspected acute primary brain lesion such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury.
  • Proven or suspected spinal cord injury or other pathology that may result in permanent or prolonged weakness.
  • Admission as a consequence of a suspected or proven drug overdose
  • Mean arterial pressure (MAP) < 50 mmHg despite adequate resuscitation and vasopressor therapy at time of randomization.
  • Death is deemed to be imminent or inevitable during this admission and either the attending physician, patient or substitute decision maker is not committed to active treatment.
  • Patients with severe hepatic impairment (Child-Pugh class C) or end stage renal disease (ESRD) (creatinine clearance < 30 ml/min or on chronic hemodialysis) due to altered pharmacokinetics [20].
  • Need for deep sedation such as administration of neuromuscular blockers.
  • Convulsions or previous history of convulsions.
  • Risk of urinary retention linked to uretroprostatic disorders.
  • Risk of acute angle glaucoma.
  • Known intolerance of or hypersensitivity to study medications or constituents.

Treatment and study plan

Nefopam

Drug

Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.

Other names: Acupan

Standard of care in the ICU for assessment and management of pain, sedation, and delirium.

Drug

In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).

Other names: Standard of care

Primary outcomes

  1. Cumulative dose of fentanyl

    Time frame: First 24 hour after randomization.

    To compare the cumulative dose of fentanyl

Secondary outcomes

  1. Richmond Agitation and Sedation Score (RASS)

    Time frame: First 24 hours after randomization.

    To compare number of patients are in RASS score goal. RASS score minumum -5 (unarousable), maximun +4 (Combative). Goal RASS score from -1 (drowsy) to 0 (alert and calm).

  2. pain score

    Time frame: First 24 hours after randomization.

    To compare number of patients are in Pain score goal. If patient able to communicate we use the 0-10 numeric rating scale in a visual format (NRS-V), 0 indicate no pain and 10 indicate the worst pain imaginable.

    For patient unable to communicate we use Critical care pain observation tool (CPOT) score, a score ≥3 indicate significant pain.

  3. Duration of mechanical ventilation (MV)

    Time frame: The number of calendar days from intubation date to extubation date, until ICU discharge, death, or 28 days post-randomization, whichever comes first.

    To assess whether nefopam can help to shorten the of being mechanically ventilated.

  4. vasopressor requirements

    Time frame: First 24 hours after randomization.

    To compare vasopressors requirement

  5. Hemodynamics

    Time frame: First 24 hours after randomization.

    changes in Mean Arterial Pressure (MAP) mmHg

  6. Hemodynamics

    Time frame: First 24 hours after randomization.

    changes in Heart Rate (HR) beats/minute.

  7. ICU length of stay (LOS)

    Time frame: From randomization to ICU discharge date

    To compare ICU LOS

  8. Tracheostomy

    Time frame: 28 days post-randomization

    Tracheostomy rate

  9. Unplanned extubation (self-extubation)

    Time frame: 28 days post-randomization

    Unplanned extubation date rate

  10. Re-intubation

    Time frame: 28 days post-randomization

    Re-intubation rate

  11. Incidence of delirium

    Time frame: 24 hour after randomization

    Rate of positive confusion assessment method for the ICU (CAM-ICU) score

  12. Use of antipsychotics

    Time frame: 24 hour after randomization

    Rate of using antipsychotics for confirmed ICU-acquired delirium

  13. Use of physical restraint

    Time frame: 24 hour after randomization

    Use of physical restraint

  14. Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.

    Time frame: 28 days after randomization

    Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Oct 8, 2021
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.